20 news items
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
REGN
SNY
31 May 24
on the submission of these analyses earlier in May, the agency has determined that this additional information constituted a major amendment
MAIA Biotechnology Inc (MAIA) Stock Surges as Company Prepares to Present Promising Data at BIO International Convention
CRL
IQV
MAIA
31 May 24
or partnerships could be a major catalyst for MAIA's stock.
3. Regulatory Progress: Updates on regulatory milestones
FDA Extends Priority Review Deadline For Regeneron Pharmaceuticals And Sanof's Dupixent For The Treatment Of COPD Patients With Type 2 Inflammation To September 2024
REGN
SNY
31 May 24
trials. Based on the submission of these analyses earlier in May, the agency has now determined that this additional information constituted a major amendment to the sBLA and extended the target action date accordingly.
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
REGN
31 May 24
, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
REGN
31 May 24
inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple
wrddqfiim3coqypal7kw7cdopshacvlm4vve7iczgbqn4cq
REGN
31 May 24
information constituted a major amendment to the sBLA and extended the target action date accordingly. Regeneron and Sanofi are confident
ul6488dfz6gluk1scaw7y1t 4yfrxe0p89
REGN
31 May 24
that this additional information constituted a major amendment to the sBLA and extended the target action date accordingly. Sanofi
plsjs6wz4n3iv9pj0iwsap3ybdal3114s5bwlqrydrw9cnp d64
BHVN
REGN
29 May 24
, and major depressive disorder.
Also, the company reported positive interim data from its ongoing Phase 1 study of BHV-1300 focused
o2t7bl9o0w7pd5rv1vivr hj1t80eqdyehjhsnf50zv87uup6rdn
BHVN
REGN
29 May 24
for the vast majority of all cancers and the advanced or metastatic forms of these carcinomas represent
q0l2ko1bnau k8gg7cv7cf3k8zo283ld3wlwhs1
ABBV
ACAD
BAYRY
24 May 24
and those affecting Change Healthcare and Ascension.
As a major distributor, Cencora handles around 20% of pharmaceuticals sold
zr5zijgcn81k42egr2hwacin1ukqs822f4jfa63c7jxd5qon4uyv v21bwgc
REGN
23 May 24
% of cases reported as grade 3 or 4. The majority of TRAEs were Grade 1 to 2 (83%), with the most common being infusion-related reactions (58
6r6oei9mkmcn9s923irp5buv4qypvu2oulikwtx6z83qdkzfqx02smve
REGN
20 May 24
-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases
a95itt1sov16gcgvy0a6bl5yrzm2ecn0wp8xbtl3o419t1jyg
REGN
20 May 24
inflammation in phase 3 studies, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role
k998foybx79my6s8pulbsys7dy
REGN
17 May 24
(NASDAQ:REGN) in comparison to its major competitors within the Biotechnology industry
8a57nx5x7pr37b45b3m0trevt455p2h6gpvwkcrr wve5wx2l
REGN
13 May 24
3 trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related
r92029xn2vbmqwszspirxy2noaycz1f1ephds7vzyg63s0qk2vgpxrp9s
AAPL
AIG
AMGN
2 May 24
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.
Trader
lmjwxl7gtgx9hfukmobymoqc0lug0c06fjgyszts84echjpigug
REGN
2 May 24
, the Company is obligated to pay 2seventy bio a regulatory milestone upon the first major market approval of the first approved product; and, with respect
ovu47fo92n0xu9d12jxzbp00xubayikf3bj2z
REGN
30 Apr 24
of 418,490.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers
exz5ms8tnbzxa765vh uhnaj8vzinb7yx3vsiht9dxifxzrw23k8h1dkfac
REGN
7 Apr 24
, among patients who had at least 24 weeks of treatment, the majority achieved a very good partial response, enabling them to transition from every two
u2l7lvj2k4o3
ARGX
ATNM
MRNA
28 Mar 24
regimens with a targeted radiotherapy approach, addressing the major toxicities associated with current methods and potentially improving patient access
- Prev
- 1
- Next